Table 2.
Association between DNA mismatch repair (MMR) and/or adjuvant treatment status on the site of tumor recurrence
| No. of patients (%) with recurrence |
|||||
| No. of patients (%) without recurrence | Site of recurrence (n = 618) |
||||
| MMR status | Local only | Intra-abdominal | Distant | P | |
| MMR status and site of tumor recurrence in all patients (N = 2111)* | |||||
| pMMR | 1222 (69) | 41 (2) | 122 (7) | 387 (22) | <.001† |
| dMMR | 271 (80) | 4 (1) | 22 (6) | 42 (12) | |
| Effect of 5-FU-based treatment by MMR status on site of recurrence in stage III (n = 1340)‡ | |||||
| pMMR | |||||
| Observation§ or no 5-FU | 160 (51) | 11 (4) | 42 (13) | 99 (32) | <.001‖ |
| 5-FU-based | 571 (67) | 21 (2) | 49 (6) | 210 (25) | |
| dMMR | |||||
| Observation§ or no 5-FU | 31 (63) | 0 (0) | 4 (8) | 14 (29) | .036¶ |
| 5-FU-based | 100 (78) | 3 (2) | 11 (9) | 14 (11) | |
Prevalence and site of tumor recurrence by MMR status in stage II and III colon cancer patients treated in 5-FU-based adjuvant therapy trials. dMMR = deficient MMR; FU = fluorouracil; pMMR = proficient MMR.
P value was calculated using the two-sided χ2 test for all sites or using only the distant recurrence category.
In patients with stage III colon cancers, the effect of 5-FU-based therapy on site of recurrence was determined.
Observation is defined as surgery alone.
P value was calculated using a two-sided χ2 test.
P value was calculated using the two-sided Fisher exact test. When only distant recurrence was analyzed, the P value was .011.